Table 1.
Baseline characteristics
| Characteristic | Study 1 | Study 2 |
|---|---|---|
| n | 24 | 26 |
| Age, years | 51.3 ± 10.0 | 50.9 ± 10.9 |
| Male, % | 50 | 38 |
| Hispanic or Latino, % | 58 | 69 |
| White, black, othera, % | 79, 8, 13 | 92, 8, 0 |
| BMI, kg/m2 | 33.3 ± 4.1 | 31.5 ± 3.2 |
| HbA1c, % | 7.35 ± 1.11 | 7.28 ± 1.02 |
| HbA1c, mmol/mol | 57 | 56 |
| FPG level, mmol/l | 8.94 ± 3.13 | 9.31 ± 3.17 |
| Prior metformin use, % | 71 | 73 |
| Washout, days | 23 (20–26) | 23 (16–36) |
| Prior DPP-4i use, % | 0 | 8 |
| Washout, days | – | 22 (16–28) |
Data are the mean ± SD or mean (range) for the intent-to-treat population, which includes all randomised participants who received at least one dose of study medication; percentages are based on the number of randomised participants in each study
aOther includes Asian, Pacific Islander/Native Hawaiian or American Indian/Alaska Native